TY - JOUR
T1 - Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: A randomised controlled trial (ViDiKids)
AU - Middelkoop, Keren
AU - Micklesfield, Lisa
AU - Stewart, Justine
AU - Walker, Neil
AU - Jolliffe, David A.
AU - Mendham, Amy E.
AU - Coussens, Anna K.
AU - Nuttall, James
AU - Tang, Jonathan
AU - Fraser, William D.
AU - Momand, Waheedullah
AU - Cooper, Cyrus
AU - Harvey, Nicholas C.
AU - Wilkinson, Robert J.
AU - Bekker, Linda-Gail
AU - Martineau, Adrian R.
N1 - Funding information: This research was funded by the UK Medical Research Council (refs MR/R023050/1 and MR/M026639/1, both awarded to AM). RJW is supported by The Francis Crick Institute which receives funding from Wellcome (CC2112), Cancer Research UK (CC2112) and UK Research and Innovation (Medical Research Council CC2112). He also receives support from Wellcome (203135) and in part by the NIHR Biomedical Research Centre of Imperial College NHS Trust.
PY - 2024/4/10
Y1 - 2024/4/10
N2 - Objective: To determine whether weekly oral vitamin D supplementation influences growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren. Design: Phase 3 double-blind randomised placebo-controlled trial. Setting: Socioeconomically disadvantaged peri-urban district of Cape Town, South Africa. Participants: 1682 children of black African ancestry attending government primary schools and aged 6-11 years at baseline. Interventions: Oral vitamin D 3 (10 000 IU/week) versus placebo for 3 years. Main outcome measures: Height-for-age and body mass index-for-age, measured in all participants; Tanner scores for pubertal development, spirometric lung volumes and body composition, measured in a subset of 450 children who additionally took part in a nested substudy. Results: Mean serum 25-hydroxyvitamin D 3 concentration at 3-year follow-up was higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference (MD) 39.7 nmol/L, 95% CI 37.6 to 41.9 nmol/L). No statistically significant differences in height-for-age z-score (adjusted MD (aMD) -0.08, 95% CI -0.19 to 0.03) or body mass index-for-age z-score (aMD -0.04, 95% CI -0.16 to 0.07) were seen between vitamin D versus placebo groups at follow-up. Among substudy participants, allocation to vitamin D versus placebo did not influence pubertal development scores, % predicted forced expiratory volume in 1 s (FEV1), % predicted forced vital capacity (FVC), % predicted FEV1/FVC, fat mass or fat-free mass. Conclusions: Weekly oral administration of 10 000 IU vitamin D 3 boosted vitamin D status but did not influence growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren. Trial registration numbers ClinicalTrials.gov NCT02880982, South African National Clinical Trials Register DOH-27-0916-5527.
AB - Objective: To determine whether weekly oral vitamin D supplementation influences growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren. Design: Phase 3 double-blind randomised placebo-controlled trial. Setting: Socioeconomically disadvantaged peri-urban district of Cape Town, South Africa. Participants: 1682 children of black African ancestry attending government primary schools and aged 6-11 years at baseline. Interventions: Oral vitamin D 3 (10 000 IU/week) versus placebo for 3 years. Main outcome measures: Height-for-age and body mass index-for-age, measured in all participants; Tanner scores for pubertal development, spirometric lung volumes and body composition, measured in a subset of 450 children who additionally took part in a nested substudy. Results: Mean serum 25-hydroxyvitamin D 3 concentration at 3-year follow-up was higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference (MD) 39.7 nmol/L, 95% CI 37.6 to 41.9 nmol/L). No statistically significant differences in height-for-age z-score (adjusted MD (aMD) -0.08, 95% CI -0.19 to 0.03) or body mass index-for-age z-score (aMD -0.04, 95% CI -0.16 to 0.07) were seen between vitamin D versus placebo groups at follow-up. Among substudy participants, allocation to vitamin D versus placebo did not influence pubertal development scores, % predicted forced expiratory volume in 1 s (FEV1), % predicted forced vital capacity (FVC), % predicted FEV1/FVC, fat mass or fat-free mass. Conclusions: Weekly oral administration of 10 000 IU vitamin D 3 boosted vitamin D status but did not influence growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren. Trial registration numbers ClinicalTrials.gov NCT02880982, South African National Clinical Trials Register DOH-27-0916-5527.
KW - Adolescent Health
KW - Growth
UR - http://www.scopus.com/inward/record.url?scp=85190368459&partnerID=8YFLogxK
U2 - 10.1136/bmjpo-2024-002495
DO - 10.1136/bmjpo-2024-002495
M3 - Article
VL - 8
JO - BMJ Paediatrics Open
JF - BMJ Paediatrics Open
SN - 2399-9772
IS - 1
M1 - e002495
ER -